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Introduction: Cardiac involvement is frequent in systemic amyloidosis and is the 
most important determinant of clinical outcome. The aims of this study were to 
assess the incidence and prognosis of cardiac amyloidosis and discuss diagnostic 
issues related to cardiac amyloidosis.  
Methods: We retrospectively studied all patients diagnosed with systemic 
amyloidosis who presented to our institution from January 1999 to December 2011.  
Results: Of the 129 patients with systemic amyloidosis,cardiac amyloidosis was 
diagnosed in 62 patients. At a mean of 3 years’ follow-up of the patients with 
systemic amyloidosis, there was statisticallysignificant difference in mortality 
between patients with cardiac amyloidosis and the rest of the patients (38.3% vs. 
14.2%, log rank p = 0.014). And decreased LV function was theonly factor 
independently associated withsurvivalin cardiac amyloidosis patients in both 
univariate and multivariate analysis(HR3.936, 95% CI1.247-12.425, p = 0.020). In 
the diagnosis of monoclonal gammopathy, serum or urine PEPis not sensitive 
enough to be used clinically compared to serum FLC assay (35.8%vs. 96.4%). 
Conclusions: In systemic amyloidosis, cardiac involvement is the most important 
determinant ofprognosis and decreased LV function was independently associated 
withsurvivalin cardiac amyloidosis patients.  
------------------------------------- 
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Amyloidosis is a clinical disorder caused by extracellulardeposition of insoluble 
abnormal fibrils, derived from aggregationof misfolded normally soluble protein1,2. 
Many different proteins can formamyloid fibrils, and the types of amyloidosis are 
classified onthe basis of the amyloidogenic protein as well as by the distributionof 
amyloid deposits as either systemic or localized3. In systemic amyloidosis, amyloid 
depositsare present in the viscera, blood vessel walls, and connectivetissues. In 
contrast, in localized disease, the deposits are confinedto specific foci or to a 
particular organ or tissue. 
The heart is notinfrequently involved in systemic amyloidosis. However, 
diagnosis of cardiac involvement is not easy and frequently underdiagnosed. 
Making an early diagnosis of cardiac amyloidosis iscritical because, once clinically 
significant heartdisease is present, the prognosis is extremely poor. 
The gold standard test for diagnosis of cardiac amyloidosis is endomyocardial 
biopsy4, but cannot be performed in every patient because of its invasiveness. 
Thus, in clinical practice, diagnosis of cardiac amyloidosis is often made in patients 
with systemic amyloidosis when echocardiographic findings suggest infiltrative 
cardiomyopathy5-8.Recently, cardiovascularmagnetic resonance imaging (CMR) 
with late gadoliniumenhancement (LGE) sequences was shown to be useful for 
thediagnosis of cardiac involvement in systemic amyloidosis9-13. 
In the present study, we assessed the incidence and prognosis of cardiac 
amyloidosis and discuss diagnostic issues related to cardiac amyloidosis. 
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MATERIALS AND METHODS 
 
Study Population 
We retrospectively studied all patients diagnosed as systemic amyloidosis who 
presented to the Seoul National University Hospital, Korea from January 1999 to 
December 2011. This study was approved by theinstitutional review board at our 
institution. Patients were followed up and evaluated for development of clinical 
events, using electronic medical records. 
 
Methods 
Detection of the presence of monoclonal gammopahty and diagnosis of systemic 
amyloidosis. For the detection of the presence of monoclonal gammopathy, protein 
electrophoresis (PEP) for the presence of M protein or immunofixation 
electrophoresis (IEP), free light chain (FLC) assay in serum and/or urine were 
used. Diagnosis of systemic amyloidosis wasbased on histologic confirmation of 
tissue deposition of amyloid. At the time of histologic confirmation, specimens were 
stained with Congo red and diagnosis of amyloidosis was made when thedeposition 
of amorphous material which showed apple-green birefringenceunder the polarized 
microscope was detected14. Immunohistochemical stains using antibodies 
directedagainst serum amyloid P component, transthyretin (TTR), kappa and 
lambda light chains, and serum amyloid A were performed simultaneously15. 
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Diagnosis of cardiac amyloidosis. Diagnosis of cardiac amyloidosis was made 
when 1) amyloid deposition was demonstrated in the myocardium by the 
endomyocardial biopsy, or 2) cardiac involvement either in echocardiography or 
CMR was suggested in patient with systemic amyloidosis. Echocardiography was 
performed in all patients with systemic amyloidosis. In the echocardiographic 
findings, cardiac involvement was suggested when mean LVthickness > 12 mm 
(average of end-diastolic septaland inferolateral walls in the parasternal long-axis 
view)16 and standard 12-lead electrocardiograms (ECG) showed low voltage QRS 
(defined as a QRS amplitude <0.5 mV in all limb leads). When CMR was performed, 
cardiac involvement was suggested when there was global or subendocardial LGE 
of the myocardium. 
Other biomarkers. Cardiactroponin-I(cTNI, reference normal: < 0.5 ng/mL), B-
type natriuretic peptide (BNP, reference normal: ≤ 100 pg/ml) or pro-type 
natriuretic peptide (pro-BNP, reference normal: 0-84 pg/ml for men under 50 
years; 0-194 pg/ml for men above 50 years; 0-155 pg/ml for women under 50 
years; 0-222 pg/ml for women above 50 years) were measured. 
Diagnosis of other organ involvement in amyloidosis. The 10th International 
Symposium on Amyloid andAmyloidosis was held 18–22 April 2004, in 
Tours,France. In anticipation of this meeting, 13 leaders inthe field were invited to 
submit their institutionalcriteria, from which the current guidelines were developed. 





Data analysis was performed using SPSS version 17.0 (SPSS Inc., Chicago, 
Illinois). Discrete data are summarized as frequencies, while continuous variables 
as mean ± SD. Chi-square or Fisher’s exact test were used for comparison of 
categorical variables. The Kolmogorov-Smirnov test was used for normality test. 
Student’s t-test was used for comparison of normally distributed continuous 
variables. In case of non-normal distribution, Mann-Whitney U test, Wilcoxon 
signed rank test were used. Survival estimates andcumulative event rates were 
estimated using the Kaplan-Meier method.Risk factors for survival were evaluated 
by both, univariate and multivariate analysis using Cox proportional hazards 
model.When verifying the analyses results with stepwise forward Cox’s regression, 
a p value of 0.10 was used to exclude or include the variables. A p value of < 0.05 


















Baseline characteristics of the patients with systemic amyloidosis and cardiac 
amyloidosis are summarized in Table 1-2. From January 1999 to December 2011, 
129 patients were newlydiagnosed with systemic amyloidosis. Among them, 76 
patients (58.9%) were male, mean age was 57.2±11.5. Hypertension was found in 
34 patients (26.4%), DM in 11 (8.5%), dyslipidemia in 7 (5.4%), chronic kidney 
disease (CKD) in 25 (19.2%) and smoking history in 2 (1.6%). Cardiac 
involvement was found in 62 patients (48.1%) and kidney was second most 
commonly involved organ (n = 49, 40.0%).  
Baseline characteristics were not different between patients with cardiac 
involvement (n = 62) and without cardiac involvement(n = 67) except for theage 
and CKD.Patients with cardiac involvement were older and had less CKD than 
patients without cardiac involvement (60.1 ±9.7 vs. 54.5 ± 12.4, p = 0.006; 8.1% 
vs. 29.9%, p = 0.002). The mean follow-up periods were 725± 944.9 days, vs 
999.5±993.0 days(p = 0.111) in patient with and without cardiac involvement, 
respectively.   
 
Diagnostic characteristics 
Table 3 shows the characteristics of the patients with systemic amyloidosis (n 
= 129). Light chain (AL)amyloidosiswas present in 127 (98.4%) andsenile 
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systemic amyloidosis (SSA) in 2 (1.6%). Among the patients with AL amyloidosis, 
32 patients (25.2%) were kappa light chain type, and 75 patients (59.1%) were 
lambda light chain type. There were positive findings of serum or urine PEP in 43 
of 120 patients (35.8%), serum or urine IEP in 43 of 103 (41.7%), serum FLC 
assay in 81 of 84 (96.4%). Laboratory, ECG, echocardiographic and CMR findings 
in cardiac amyloidosis are shown in detail in Table 4. In patients with cardiac 
amyloidosis (n = 62), AL amyloidosis was present in 60 (96.8%) and SSA in 2 
(3.2%). Among the patients with cardiac involvement in AL amyloidosis, 11 cases 
(19.6%) were kappa light chain type and 45 cases (80.4%) were lambda light chain 
type. 
In the laboratory findings, 26 of 27 patients (96.3%) had elevation of BNP or 
pro-BNP. Endomyocardial biopsy was available in 30 patients and positive 
pathology compatible with cardiac amyloidosis was present in 29 patients (96.6%). 
There was low voltage QRS at ECG in 53 of 62 patients (85.5%)(Figure 1). 
Echocardiography was available in all patients. Among them, increased LVwall 
thickness was present in 60patients (96.8%), decreased LV function in 31 (50.0%), 
pericardial effusion in37 (60.7%) and diastolic dysfunction in 42 (68.9%)(Figure 2). 
CMR was also available in 15 patients and positive finding was present in 13 
(86.7%)(Figure 3). In detail, 29 patients were diagnosed with cardiac involvement 
by endomyocardial biopsy, and among the rest of the patients (n = 33), cardiac 
involvement was suggestedby the echocardiographic findings in 29 patients and 




Survival and Prognosis 
At a mean of3 years’ follow-up of the patients with systemic amyloidosis, 
death had occurred in 17 cases in patients with cardiac involvement (n = 62) and 8 
patients without cardiac involvement (n = 67). There werestatisticallysignificant 
differences in mortality at a mean of3 years’ follow-up (38.3% vs. 14.2%, log 
rankp = 0.014)(Figure 4). 
Regarding to the effect of treatment (chemotherapy, autologous stem cell 
transplantation and cardiac transplantation) on the prognosis, in patients with 
systemic amyloidosis, death had occurred in 20 cases in treatment group (n = 100) 
and 5 cases in no-treatment group (n = 29). There was no statisticallysignificant 
difference in mortality between the groups (25.6% vs. 20.9%, log rankp = 
0.771)(Figure 5). In addition, no significant effect of treatment on the prognosis 
was also noted in patients with cardiac amyloidosis, at a mean of3 years’ follow-up. 
Death had occurred in 14 cases in treatment group (n = 52) and 3 cases in no-
treatment group (n = 10)(37.4% vs. 33.3%, log rankp = 0.316)(Figure 6). 
In univariateanalysisof the patients with cardiac involvement, decreased LV 
function was the only significant variable associated with survival. After 
multivariate analysis, decreased LV function was theonly factor independently 
associated withsurvival, with a hazard ratio of 3.936 (p = 0.020; 95% 






Table 1. Baseline characteristics in patients with amyloidosis 
 Systemic  
amyloidosis 
(n = 129) 
With cardiac 
involvement 




(n = 67) 
 
*p value 
Age, years 57.2 ± 11.5 60.1 ± 9.7 54.5 ± 12.4 0.006 
Male, n (%) 76 (58.9%) 32 (51.6%) 44 (65.7%) 0.112 
HTN, n (%) 34 (58.9%) 18 (29.0%) 16 (23.9%) 0.552 
DM, n (%) 11 (8.5%) 3 (4.8%) 8 (11.9%) 0.210 
Dyslipidemia, n (%) 7 (5.4%) 3 (4.8%) 4 (6.0%) > 0.999 
Smoking History, n (%) 2 (1.6%) 1 (1.6%) 1 (1.5%) > 0.999 
CKD, n (%) 25 (19.4%) 5 (8.1%) 20 (29.9%) 0.002 
Treatment, n (%) 100 (77.5%) 52 (83.9%) 48 (71.6%) 0.139 







* p value between with cardiac involvement and without cardiac involvement 









Table 2. Frequency of organ involvement in patients with systemic amyloidosis 
Systemic amyloidosis (n = 129) 
Involved organs, n (%)  
    Heart 63 (48.8%) 
    Kidney 49 (40.0%) 
    Gastrointestinal tract 20 (15.5%) 
Soft tissue 10 (7.8%) 
    Liver 9 (7.0%) 
    Lung 5 (3.9%) 
















Table 3. Patients’laboratory characteristics in systemic amyloidosis 
Systemic amyloidosis (n = 129) 
Types, n (%)  
     AL amyloidosis 127 (98.4%) 
     SSA 2 (1.6%) 
Subtypes of AL amyloidosis (n = 107)  
     Kappa light chain, n (%) 32 (25.2%) 
Lambda light chain, n (%) 75 (59.1%) 
Laboratory characteristics  
Positive of serum or urine PEP (n = 120) 43 (35.8%) 
Positive of serum or urine IEP (n = 103) 43 (41.7%) 
 Positive of serum FLC assay (n = 84) 81 (96.4%) 
     Positive of immunohistochemistry (n = 63) 43 (68.3%) 
AL, amyloid light chain; SSA, senile systemic amyloidosis; PEP, protein 











Table 4. Patients’laboratory, ECG, echocardiographic and CMRcharacteristics in 
cardiac amyloidosis 
Cardiac amyloidosis (n = 62) 
Types of amyloidosis (n = 62)  
     AL amyloidosis, n (%) 60 (96.8%) 
     SSA, n (%) 2 (3.2%) 
Subtypes of light chain (n = 56)   
     Kappa light chain, n (%) 11 (19.6%) 
Lambda light chain, n (%) 45 (80.4%) 
Laboratory characteristics, n (%)  
     Elevation of cTNI (n = 18) 0 (0%) 
Elevation of BNP or pro-BNP (n = 26) 25 (96.2%) 
Endomyocardial biopsy (n = 30)  
Positive pathology, n (%) 29 (96.6%) 
ECG characteristics(n = 62)  
Low voltage QRS, n (%) 53 (85.5%) 
Echocardiographic characteristics (n = 62)  
     Positive echocardiography, n (%) 60 (96.8%) 
     LV EF < 50%, n (%) 31 (50.0%) 
     Presence of pericardial effusion, n (%) 37 (60.7%) 
     Presence of diastolic dysfunction, n (%) 42 (68.9%) 
CMR characteristics(n = 15)  
     Positive CMR, n (%) 13 (86.7%) 
１２ 
 
AL, amyloid light chain; SSA, senile systemic amyloidosis; cTNI, cardiactroponin-I; 
BNP, B-type natriuretic peptide; pro-BNP, pro-B-type natriuretic peptide; B2MG, 
beta-2-microglobulin; PEP, protein electrophoresis; IEP, immunofixation 
electrophoresis, FLC, free light chain; LV EF, Left ventricular ejection fraction; 






















Table 5. Prognosis valuables for cardiac amyloidosis 
Univariate Analysis Multivariate Analysis 
Variables p value Hazard Ratio (95% CI) p value 
Low voltage QRS 0.602 0.506 (0.137-1.869)  0.307 
Increased LV wall thickness 0.681 0.276 (0.028-2.720)  0.270 
Decreased LV function 0.030 3.936 (1.247-12.425)  0.020 
Pericardial effusion 0.486 1.368 (0.520-3.596)  0.525 
Diastolic dysfunction 0.754 1.036 (0.361-2.973)  0.947 

















Figure 1. ECG in a patient with cardiac amyloidosis. Note the low voltage QRS in 

















Figure 2. Echocardiography in a patient with cardiac amyloidosis.Top left and right, 
parasternal long-axis and apical four chamber view demonstrates concentric left 
ventricular thickening with small amount of pericardial effusion. Bottom left and 












Figure 3. CMR in a patient with cardiac amyloidosis. Top row shows diastolic 
frames from cines (vertical long axis, horizontal longaxis, and short axis, 
respectively) showing a thickened left ventricular wall and presence of pericardial 
effusions. Bottom row shows LGE images in the same planes. The vertical and 
horizontal longaxis image demonstrates global subendocardial hyperenhancement 
ofboth ventricles, both atria and the interatrial septum(white arrows). 
 









Figure 4. Kaplan-Meier survival curves of patients with systemic amyloidosis with 











Figure 5. Kaplan-Meier survival curves of patients with systemic amyloidosis with 











Figure 6. Kaplan-Meier survival curves of patients with cardiac amyloidosis with 













Cardiac involvement is frequent in systemic amyloidosisand is a major 
determinant of treatment optionsand prognosis17.Cardiac involvement is observed 
in about 50% of the patients with AL amyloidosis18 and is the cause of death 
inapproximately half of patients with AL amyloidosis19. And fewer than 5% of the 
patients with AL amyloidosis involving the heart have clinically isolated cardiac 
disease20. In our study, cardiac involvement was demonstrated in 48.8% cases of 
systemic amyloidosis, mostly by the AL amyloidosis, only 2 patients was proven to 
be SSA, and there was no patient with isolated cardiac involvement.  
 
Diagnostic Issues in Systemic Amyloidosis 
Once a tissue diagnosis of amyloidosis has been established,confirmation of AL 
amyloidosis, which is the most frequent type of systemic amyloidosis with cardiac 
involvement, requires demonstration of a monoclonal gammopathy. Presence of 
monoclonal gammopathy can be demonstrated by the bone marrow biopsy showing 
predominanceof kappa or lambda producing plasma cells or by the presence of 
amonoclonal light chain in the serum or urine. Between PEP and IEP/FLC assay, 
IEP or FLC assay is favored because of the high sensitivity compared to PEP.  
In the present study, we confirmed the very high sensitivity of serum FLC 
assay in the diagnosis of AL amyloidosis with the sensitivity of 96.4% in contrast 
to low sensitivity in serum or urine PEP (35.8%). This finding is supported by 
several studies21,22. Morris et al reported that in study of 31 AL amyloidosis 
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patients, serum and urine PEP was positive in 30%, serum IEP in 67%, urine IEP in 
83%,serum and urine IEP in 90%, absolute clonal light chain ≥ 100 mg/Lin 87%, 
and abnormal kappa lambda ratio with increased clonal light chain in 97%23. Normal 
FLC assay result in thepresence of biopsy-proven amyloidosis should lead toa 
thorough search for SSA or familial amyloidosis.  
 
Diagnostic Issues in Cardiac Amyloidosis 
Although the gold standard for diagnosis of cardiac amyloidosis is 
endomyocardial biopsy,ECG is considered a key player to orient diagnostic 
suspicion of cardiac amyloidosis, with low voltageQRS providing a particularly 
valuable noninvasive clue.Dubrey et al reported that more than 70% of the patients 
with AL cardiac amyloidosis exhibited low voltage amplitudes20 and in another 
series, Murtagh et al found that only 46% of the patients with primary systemic 
amyloidosis and biopsy-proven cardiac involvement exhibited lowvoltage 
amplitudes24. 
The most common echocardiographic feature is thickening of the LV wall5,8,25-28. 
The combination of increased LV mass in the absence of high ECG voltages may be 
more specific for infiltrative diseases, of which amyloid is the most common25,29. 
High sensitivity (72% to 79%) and specificity (91% to 100%) have been reported 
for this combination27,29. In the present study, low voltageQRS was present in 84.1% 
and increased LVwall thickness was present in 96.8% of the patients.  
CMR imaging now has an established role in the diagnosis of cardiac 
involvement. Although, CMR was available only in small number of the patients in 
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the present study, LGE in aglobal or subendocardial distributionwas present in 13 
of 15 (86.7%) patients, similar to the study of Perugini13. He reported that 
gadolinium enhancement by CMR was detected in 16 of 21(76%) patientswith 
histologically proven systemic amyloidosis andechocardiographic diagnosis of 
cardiac involvement13.Subsequent studies have substantiatedthe diagnostic value of 
CMR with LGE in identifying cardiacinvolvement, and suggested that the presence 
of LGE may confers prognostic information12,30,31. 
 
Survival and Prognosis in Cardiac Amyloidosis 
The prognosis of the amyloidosis varies, but it isgenerally poor if the disease is 
untreated.Among various prognostic factors, the extentof cardiac involvementis the 
most important determinant of clinical outcome17,32,33. In the present study, the 
survival is worse in patients with cardiac involvement than without cardiac 
involvement and 1-year, 2-year and 3-year survival of the patients with cardiac 
involvement were 72.8%, 69.8% and 61.7%, respectively. And 82.3% patients were 
treated with chemotherapy, 19.4% with autologous stem cell transplantation and 
4.8% with cardiactransplantation. The survival rates of our study were markedly 
better than in the study of Kyle, who reported a 1-year survival of approximately 
30%34 and similar to the previous study of Kristen, who reported 1- and 3-year 
survival of 68% and 63%32, respectively. Deaths were more in patients noteligible 
for high-dose chemotherapy and autologous stemcell transplantation indicating a 
marked beneficial effect ofthis potentially curative treatment approach on 
survival.High-dose melphalan chemotherapy andautologous stem cell 
２３ 
 
transplantation is generally accepted asa therapeutic approach to improve 
survival35-37 andquality of life38in AL amyloidosis. 
Previously proposed associations with poor prognosis in cardiac amyloidosis 
include reduced EF, increased LV wall thickness on echocardiography, low voltage 
QRSin ECG, and the type of amyloidosis (with worse prognosis in AL compared 
with TTR type)32. In addition, the degree of diastolic dysfunction33 and suppression 
of amyloidogenic serum light chains by chemotherapy, and lower baseline values 
and greater reductions in pro-BNP have been associated with improved 
outcome39,40. In the present study, only decreased LV function was associated with 
survival with marginal significancein both univariate and multivariate analysis.  
 
Study Limitations 
First, given the rarity of systemic amyloidosis and cardiac amyloidosis, patient 
numbers were relatively small although we reviewed 13-years’ medical records 
from our institution. Therefore, some detailed comparisons were outside the scope 
of this study, and further work is needed for this. Second, a large loss to follow-up 
of our study may be a particular source of bias. For example, in case of the 
patients with systemic amyloidosis, 61 in 129 patients (47.3%) and with cardiac 
amyloidosis, 25 in 62 patients (40.3%) were lost to follow-up. Third, cardiac 
histology was only present in a subset of patients, and the decision to perform a 
cardiac biopsy was made on clinical grounds, which may introduce bias. Finally, 
though CMR shows promise for diagnosing cardiac amyloidosis if echocardiographic 
features are suspicious, CMR was only available in 24.2% of the patients with 
２４ 
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서론:전신성 유전분증에서 심장 침범은 흔하게 관찰되며, 심장 침범 여부는 임상 경과에 
가장 중요한 영향을 미치는 인자이다. 이 연구의 목적은 심장 유전분증의 발병률과 
예후를 확인하고 심장 유전분증 진단과 관련된 쟁점에 대하여 논의하는 데에 있다.  
방법:우리는 본 연구를 위하여 1999 년 1 월부터 2011 년 12 월까지 서울대병원에서 
전신성 유전분증을 진단받은 모든 환자를 후향적으로 연구하였다.  
결과:상기 기간 동안 전신성 유전분증으로 진단된 129 명의 환자 중에, 62 명은 심장 
유전분증으로 진단되었다. 전신성 유전분증 환자에 대하여 3 년의 추적 관찰 기간 동안, 
심장 침범이 있는 경우, 없는 경우보다 통계적으로 유의하게 사망률이 높았다. (38.3% 
vs. 14.2%, log rank p = 0.014). 또한, 단변량 및 다변량 분석 결과, 좌심실 기능 
감소는 통계적으로 유의하게 독립적으로 사망률을 높일 수 있음이 확인되었다 (HR 
3.936, 95% CI 1.247-12.425, p = 0.020). 또한, 단클론성 감마병증 진단과 관련하여, 
혈청 혹은 소변을 검체로 하는 단백영동검사는 유리형 경쇄 분석 검사만큼 민감도가 
높지 않았다. (35.8% vs. 96.4%)  
결론:전신성 유전분증에서, 심장 침범의 여부는 예후의 가장 중요한 결정 인자이며, 
좌심실 기능 감소는 독립적으로 심장 유전분증 환자의 사망률을 높인다. 
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